News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
NxStage Medical, Inc. Cuts Expected IPO Price Range
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 26 (Reuters) - Medical device company NxStage Medical Inc. cut the expected price for its initial public offering to between $11 and $12 a share from a previous range of $13 to $15, according to a regulatory filing on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Drug Development
CRO Boom in APAC region, With China at the Forefront
November 19, 2025
·
5 min read
·
Jennifer Smith-Parker
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
November 19, 2025
·
9 min read
·
Tristan Manalac
Mergers & acquisitions
J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash
November 17, 2025
·
2 min read
·
Dan Samorodnitsky
Collaboration
Lilly Bets More Than $2.6B for South Korea Biotech’s Bispecific Antibody Platform
November 17, 2025
·
2 min read
·
Tristan Manalac
